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IL-9 Regulates Allergen-Specific Th1 Responses in
Allergic Contact Dermatitis
Juan Liu1, Erin Harberts1,2, Antonella Tammaro1,3, Nicholas Girardi4, Renata B. Filler5, Rita Fishelevich1,
Angela Temann6, Paula Licona-Limo´n6, Michael Girardi5, Richard A. Flavell6 and Anthony A. Gaspari1,2
The cytokine IL-9, derived primarily from T-helper 9 (Th9) lymphocytes, promotes expansion of the Th2 subset
and is implicated in the mechanisms of allergic asthma. We hypothesize that IL-9 also has a role in human allergic
contact dermatitis (ACD). To investigate this hypothesis, skin biopsy specimens of positive patch–test sites from
non-atopic patients were assayed using quantitative PCR and immunohistochemistry. The cytokines IFN-g, IL-4,
IL-17A, IL-9, and PU.1, a Th9 associated transcription factor, were elevated when compared with paired normal
skin. Immunohistochemistry on ACD skin biopsies identified PU.1þCD3þ and PU.1þCD4þ cells, consistent with
Th9 lymphocytes, in the inflammatory infiltrate. Peripheral blood mononuclear cells from nickel-allergic patients,
but not nonallergic controls, show significant IL-9 production in response to nickel. Blocking studies with mAbs
to HLA-DR (but not HLA-A, -B, -C) or chloroquine significantly reduced this nickel-specific IL-9 production. In
addition, blockade of IL-9 or IL-4 enhanced allergen-specific IFN-g production. A contact hypersensitivity model
using IL-9 / mice shows enhanced Th1 lymphocyte immune responses, when compared with wild-type mice,
consistent with our human in vitro data. This study demonstrates that IL-9, through its direct effects on Th1 and
ability to promote IL-4 secretion, has a regulatory role for Th1 lymphocytes in ACD.
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INTRODUCTION
After activation, naive CD4þ T-helper (Th) cells differentiate
along separate lineages into effector T-cell subsets depending
on the type of antigen recognized and the selection of
cytokines present within the adjacent extracellular milieu.
The traditional Th1 or Th2 paradigm has expanded to include
Th17, Th9, Treg, and Th22 cells, each with lineage-specific
transcription factors and production of a distinct array of
cytokines (Wan and Flavell, 2009). Our understanding of the
interplay between these cells and their involvement in immune
pathology is still incomplete. IL-9 is classically considered to
be associated with the Th2 subset. However, recently an IL-9-
producing T-cell subset, named Th9, has been recognized and
is implicated in the pathogenesis of allergic inflammation
(Dardalhon et al., 2008; Veldhoen et al., 2008).
IL-9 is shown to have pleiotropic cellular effects involved
in promoting allergic inflammation, including inducing mast
cell growth and survival, eotaxin production, and goblet cell
metaplasia (Vermeer et al., 2003; Gounni et al., 2004; Kearley
et al., 2011). A significantly elevated level of IL-9 has been
found in bronchial biopsies from patients with atopic asthma
compared with matched controls, and thus IL-9 may have
a significant role in the chronic airway inflammation and
bronchial hyperresponsiveness seen in asthmatic disease (Ying
et al., 2002). Blocking IL-9 inhibits airway remodeling and
mastocytosis in a model of chronic lung inflammation (Kearley
et al., 2011). A recent study shows that Th9 cells are generated
in vivo after epicutaneous sensitization by patch application
with ovalbumin in mice (Lin et al., 2012). PU.1, an ETS (E26
transformation specific or E-twenty-six)-family transcription
factor, has since been identified as a main regulator of IL-9
production in human Th9 cells. Increased PU.1 expression is
associated with a decrease in Th2 cytokines and increased
phenotypic characteristics consistent with Th9 cells, including
production of IL-9. In addition, less allergic inflammation was
seen in the lungs of mice with PU.1-deficient T cells
compared with their wild-type (WT) counterparts (Chang
et al., 2010). Despite their known role in allergic lung
disease, their participation in allergic contact dermatitis
(ACD) has not been established.
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In this study, we examine IL-9 expression and the frequency
of PU.1-positive T lymphocytes (Th9 lymphocytes) infiltrating
into positive patch–test reactions to a variety of allergens. We
identify allergen-specific IL-9 production by PBMCs (peripheral
blood mononuclear cells) from a group of seven patients with
positive patch tests to nickel. Our data show that IL-9
and related cytokine gene expression as well as PU.1þCD4þ
T cells are significantly increased in positive patch–test biopsies
from these allergic patients. In vitro experiments show IL-9
synergizing with signature cytokines from Th2 lymphocytes and
regulating Th1 lymphocyte allergen-specific responses. The role
of IL-9 found in our in vitro human data was confirmed using
an in vivo mouse model, by studying contact hypersensitivity
(CHS) to DNFB in IL-9 gene–targeted mice (IL-9 / ). This
mouse model confirmed the regulatory role of IL-9 in CHS.
RESULTS
The genes encoding IL-9 and Th9-associated transcription factor,
PU.1, are elevated in ACD
We measured IL-9 and other cytokine genes associated with
ACD in positive patch tests, as well as in paired normal skin.
The mean relative gene expression of IL-9 (Figure 1a) was
elevated on average fivefold (range 2–18) higher than in
paired normal skin. This was equivalent to the mean change
in gene expression for IFN-g, IL-4, and IL-17A. We also
studied Th9-associated transcription factors PU.1, ETS-1, IFN
regulatory factor 4, and GcN5 (Oikawa and Yamad, 2003;
Refaat et al., 2011, Goswami and Kaplan, 2012), which were
all similarly elevated two- to threefold (range 1.5–8) higher
than in paired control skin (Figure 1b).
Th9 lymphocytes, but not CD8þ /PU.1þ lymphocytes, are
detectable in the inflammatory infiltrate of ACD
Immunochemistry was performed for Th9 transcription factor
PU.1 and T-cell surface markers (CD3, CD4, or CD8) in
positive patch–test biopsies from five patients with ACD to
different allergens. Either CD3þ /PU.1þ or CD4þ /PU.1þ
double-positive cells were readily identifiable in the cellular
infiltrates of ACD, present in both the dermis and the
epidermis (Figure 1c). Of the total population of infiltrating
CD3þ /CD4þ T cells, B4% were PU.1þ (Figure 1d and e).
There were no CD8þ /PU.1þ double cells detected in ACD
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Figure 1. Increased expression of IL-9 and associated genes in allergic contact dermatitis (ACD) and the detection of Th9 cells in allergic contact dermatitis.
(a) Mean relative-gene expression of IL-9 was elevated on average fivefold (range 2–18) higher than that in paired control skin. IL-9 increase is similar to increases
in IFN-g, IL-4, IL-17A, CCL11, and CD3e. (b) Mean relative-gene expression of IL-9/Th9-associated transcription factors PU.1, IRF4, ETS-1, and GcN5 was
two- to threefold (range 1.5–8) greater than that in paired control skin. Sections of skin biopsy specimens from a representative. Sections of skin biopsy specimens
from a representative sample. (c) Stained slides from an ACD patient were stained with anti-PU.1 (red) and anti-CD4 (green); nuclei are counterstained with
40,6-diamidino-2-phenylindole (DAPI) (blue). Stained T lymphocytes were identified as (d) PU.1þ /CD3þ or (e) PU.1þ /CD4þ . No PU.1þ /CD8þ cells were
identified. To quantify cell populations, 12 fields from each double-stained section were counted with a mean of 40 infiltrating cells per field. Mean±SEM is
depicted. For gene expression studies, skin biopsy samples were taken from positive patch tests to nickel or cobalt from seven different patients (ACD6–12 in
Table 1). For the immunochemistry, skin biopsy specimens were taken from five different positive patch tests in five different patients (ACD1–5 in Table 1).
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(Figure 1e). No PU.1-positive T cells were detectable in the
normal skin samples that were examined (data not shown).
Allergen-specific IL-9 production in vitro by PBMCs from nickel
allergic patients
Next, we investigated nickel-specific cytokine production in
lymphocytes from seven different nickel-allergic patients. We
measured levels of IL-9, IFN-g, IL-2, and IL-4 in culture
supernatant in response to in vitro challenge with nickel or
cobalt chloride, a nonallergic metal salt as confirmed by patch
test. In several patients, we observed a robust dose-dependent
production of IL-9 in response to increasing doses of nickel
(Figure 2a). In contrast, PBMCs derived from two patients that
were tolerant of nickel (negative patch tests), their PBMCs did
not produce detectable IL-9 in response to nickel challenge
in vitro (Figure 2a). To confirm that PBMCs have a similar
capacity for the production of IL-9 in the nickel-allergic and -
tolerant patients, we studied mitogen-induced IL-9 production
(Figure 2b). Both groups produced high levels of IL-9 in
response to phytohemagglutinin stimulation, which was
equivalent between the two groups. In the nickel-allergic
patients who had negative patch tests to cobalt chloride there
was no IL-9, or other cytokines, produced in response to the
irrelevant control metal salt, cobalt chloride (data not shown).
From the dose-response curves of nickel-specific cytokine
production, we plotted the peak cytokine production from
each of the seven nickel-allergic patients (Figure 2c). The
mean peak cytokine production of both IFN-g and IL-9 was
significantly higher than IL-4. These data indicate that aller-
gen-specific IL-9 production is at a similar level as IFN-g in
patients with ACD to nickel.
Characterization of antigen-presenting cell pathways for
recognition of nickel-specific IL-9 production
In order to elucidate how Th9-specific antigens are being
processed and presented, blocking studies were performed.
A mAb specific for HLA-DR, associated with the major
histocompatibility complex class II (MHC II) pathway, sig-
nificantly attenuated nickel-specific IL-9 production, whereas
anti-HLA-A, -B, or -C had no significant effect on IL-9
(Figure 3). Similarly, pre-incubation of PBMCs with chloro-
quine, before nickel stimulation, also significantly attenuated
nickel-specific IL-9 (Figure 3). These data indicate that
allergen-induced IL-9 production is dependent on the MHC
class II pathway and requires processing. This is consistent
with the in situ data in which we observed CD4þPU.1þ
T lymphocytes, but not CD8þPU.1þ T lymphocytes in ACD
(Figure 1).
Regulatory role of IL-9 in ACD
We next investigated whether IL-9 modulates nickel-specific
IFN-g production. As expected, exogenous IL-4 significantly
decreased nickel-specific IFN-g production by PBMCs from a
nickel-allergic patient, and exogenous IL-9 did not attenuate
nickel-specific IFN-g production (Figure 4a). When exogenous
IL-9 and IL-4 were added simultaneously to lymphocyte
cultures, the inhibitory effects of IL-4 on IFN-g production
were dominant and were not influenced by the presence of
IL-9. We also studied the cross-regulation of IL-9 and IL-4
during allergen-specific responses (Figure 4b and c). Exogenous
IL-9 augmented nickel-specific IL-4 (Figure 4b) and exogenous
IL-4 augmented nickel-specific IL-9 (Figure 4c). These
data suggest that there is synergy between Th2 and Th9
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Figure 2. Allergen-specific IL-9 production by peripheral blood mononuclear
cells (PBMCs) from nickel-allergic patients. PBMCs were isolated from seven
different patients with allergic contact dermatitis to nickel (Table 1) and
cultured with nickel chloride (1–10mg ml1 of culture medium) for 96 hours.
Supernatants were harvested, and the following cytokines were assayed in cell-
free culture supernatants: IL-9, IFN-g, IL-4, and IL-2 (data depicted represent
mean ± SD of samples assayed in triplicate). (a) Dose–response curve to
nickel titration from two nickel-allergic patients and two nickel-tolerant
patients. (b) IL-9 production from the same two nickel-allergic and -tolerant
patients, demonstrating that both groups can produce IL-9 in an equivalent
manner after phytohemagglutinin (PHA) stimulation. (c) Scatter plot represents
the peak cytokine production from the seven allergic patients. The scatter plot
of peak cytokine production (horizontal bar represents mean value) for both
IFN-g and IL-9 was significantly higher than that of IL-4 (Po0.001), with the
average peak IL-9 production similar to IFN-g (P40.05).
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lymphocytes via their cytokines, and also suggest an indirect
regulatory role for IL-9 in ACD. Whereas IL-9 itself does not
attenuate IFN-g production by Th1 lymphocytes, this cytokine
augments the production of IL-4, which is a known inhibitory
cytokine for Th1 lymphocytes (Mosmann et al., 1986; Cher
and Mosmann, 1987; Yip et al., 1999). The addition of anti-
sera to block either IL-9 or IL-4 in cultures of nickel-stimulated
PBMCs augmented IFN-g production, again indicating a
regulatory function for IL-9 (Figure 4d).
The regulatory role of IL-9 in an in vivo model of contact
hypersensitivity
To further confirm our human in vitro data, we studied contact
hypersensitivity in IL-9 gene–targeted mice (IL-9 / ), and
compared their ear swelling responses with those of WT mice
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Figure 3. IL-9 production depends on exogenous antigen presentation to Th9
lymphocytes. IL-9 production was measured 96 hours after stimulation of
peripheral blood mononuclear cells (PBMCs) with medium containing nickel
chloride (10mg ml 1). Samples are incubated with either media, anti HLA DR
mAb (0.25mg ml1 and 1mg ml1), anti-HLA-A, B, C mAbs (0.25mg ml1 and
1mg ml 1), or chloroquine (5mM and 20mM) 2 hours prior to stimulation with
nickel. Antibodies to HLA-A, B, C had little effect on IL-9 production, whereas
Abs to HLA-DR or incubation with chloroquine resulted in significantly
reduced IL-9 production. Mean þ / SD of samples assayed in triplicate is
depicted. Our results suggest that the processing of nickel via the exogenous
pathway of antigen presentation is necessary for PBMC production of IL-9. The
experiment was repeated with PBMCs from three different patients, and found
to be reproducible.
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Figure 4. IL-4, but not IL-9, directly regulates IFN-c during allergen-specific
Th1 activation in vitro. (a) Peripheral blood mononuclear cells (PBMCs) from a
nickel-allergic patient were cultured in medium alone or in medium containing
nickel chloride; the indicated doses of IL-9 alone, IL-4 alone, or IL-9 and IL-4
together were added to the nickel chloride-stimulated PBMCs. Supernatants
were collected 96 hours after nickel stimulation. (b) IL-4 secretion was also
measured after addition of IL-9. (c) IL-9 was measured in those culture
conditions, which had added IL-4. (d) Specific blocking anti-sera were added
to the nickel culture, and IFN-g was assayed using multiplex ELISA. Data
depicted represent mean ± SD of samples assayed in triplicate. This
experiment was repeated with PBMCs three times and was found to be
reproducible. The data in (a–d) represent PBMCs from distinct nickel-allergic
patients.
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of the same H-2d background. When compared with WT
mice, IL-9 / mice exhibited slightly diminished ear swelling
responses at 48 hours (Figure 5a). Histological analysis of ear
sections taken 24 hours after hapten challenge from either WT
or IL-9 / mice exhibited qualitatively similar pathologic
findings (Figure 5b). However, analysis of in situ cytokine gene
expression revealed that during CHS reaction IL-9 / mice
showed enhanced Th1 and diminished Th2 gene expression,
whereas WT have a balanced Th1–Th2 profile (Figure 5c). The
mean fold change in IFN-g gene expression was significantly
greater in IL-9 / mice compared with the WT mice
(Po0.05, analysis of variance). To better understand the
systemic effects of the role of IL-9 in contact hypersensitivity,
we studied dinitrophenyl-specific IgG1 and IgG2a in the sera
of sensitized mice 3 weeks after sensitization with topical
DNFB. Dinitrophenyl-specific IgG1 (Th2 driven) was similar
in WT and IL-9 / mice, and there was significant enhance-
ment of IgG2a (Th1 driven) in IL-9 / mice compared with
wild-type mice (Figure 5d and e). These data indicate that IL-9
exhibits a regulatory role in ACD and also that compensatory
inflammatory mechanisms operate in the absence of IL-9,
resulting in a relatively preserved ear swelling response in
which Th1 lymphocytes have a more important role both
locally and systemically. To further study the response to
inflammatory agents, we challenged naive WT and IL-9 /
mice with the topically applied irritant, 12-O-tetradecanoyl-
phorbol-13-acetate. After 24hours of application, IL-9 /
mice exhibited significantly less ear swelling compared with
WT control mice (t¼4.069, unpaired t-test, Po0.0023).
DISCUSSION
ACD is a result of a complex network of antigen-presenting
cell–T-cell interactions, and represents a balance between
effector subsets and regulatory subsets (Gober and Gaspari,
2008). Whereas CD8þ T lymphocytes are effector cells that
mediate tissue damage during the elicitation phase of ACD,
the CD4þ T-lymphocyte subset has a regulatory role in ACD
of secreting an immune suppressive milieu of cytokines
(Gocinski and Tigelaar, 1990; Bour et al., 1995; Martin
et al., 2000; Vocanson et al., 2006). In human positive
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Figure 5. The regulatory role of IL-9 in mouse contact hypersensitivity. (a) Ear swelling response of wild type (WT) or IL-9 / mice (n¼5 group1) was
measured over time. (b) Ear punches taken 24 hours after elicitation are stained with hematoxylin and eosin stain; shown are ears from WT (left) and IL-9 / mice
(right). (c) Gene expression was measured by quantitative PCR from ear skin 24 hours after elicitation. Mean± SD fold change in gene expression is shown (n¼ 4
mice/group, *Po0.05). (d) Sera (n¼5 mice/group) from WT or IL-9 / mice 21 days after sensitization were measured for DNP-specific IgG1 or (e) IgG2a by
ELISA. Levels of DNP-specific Ab from pre-bleed sera (prior to sensitization) were subtracted to calculate the net DNP-specific response. Data shown represent
mean ± SD (***Po0.001). (f) Irritant contact dermatitis to croton oil in WT and IL-9 / mice; data indicate mean ± SD (Po0.0023).
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patch–test reactions, a multitude of cytokines can be identified
(Zhao et al., 2009), suggesting that a variety of Th subsets may
be involved in ACD. Our data investigating human skin
biopsies from ACD to nickel and other clinically relevant
allergens (Table 1) are consistent with this. We found that
genes encoding several cytokines were increased in human
ACD (Figure 1). However, we also identified increased levels
of IL-9 and the Th9-associated transcription factors, PU.1, ETS-
1, IFN regulatory factor 4, and GcN5 at similar levels as these
well-known ACD-associated cytokines. These results suggest
that Th9-derived IL-9, as well as other classically associated
cytokines, have a role in human ACD.
We demonstrate by using biopsies from positive patch tests
that allergen-specific CD4þ /PU.1þ T cells, but not CD8þ /
PU.1þ T cells, are detectable in the efferent phase of ACD
(Figure 1). This is consistent with a regulatory, rather than a
pathogenic, role for IL-9-producing T cells in ACD. It has been
shown that lymphocytes from patients with positive patch tests
(i.e., ACD) to metal salts produce both Th-1-associated IFN-g
as well as Th2-associated IL-4 and IL-13 upon culture with the
appropriate allergen (Minang et al., 2006). When measuring
allergen-specific cytokine production of ex vivo cultured
PBMCs from ACD patients, we find that the allergen-specific
IL-9 production by ex vivo PBMCs is augmented in allergic
patients, but not in nonallergic control patients (Figures 2–4).
We were able to detect nickel-specific IL-4 at low levels,
whereas IFN-g and IL-9 showed a robust response to nickel
(Figure 2). We were not able to identify CD4þ /PU.1þ T cells
in normal human skin (data not shown). However, this cell
type constituted B4% of the inflammatory infiltrate of ACD
and we noted elevated IL-9 transcripts in ACD compared with
paired normal skin (Figure 1). These data suggest that the IL-9-
producing CD4þ /PU.1þ T cells migrate into the skin of
ACD.
Xenobiotic chemicals are thought to be chemically reactive
with host proteins, by forming haptens, which are presented
by migratory cutaneous antigen-presenting cells in the local
lymph node (Kaplan et al., 2012). Haptens can be recognized
by class I MHC–restricted CD8þ T lymphocytes, or class II
MHC–restricted CD4þ T lymphocytes. Studies of processing/
presentation of nickel to reactive T lymphocytes suggested two
pathways for nickel recognition: one involves a processing
independent pathway in which nickel binds to peptides
already loaded into MHC molecules, and the other pathway
involves a processing-dependent pathway in which nickel
binds to membrane or exogenous proteins, which are then
taken up by an antigen-presenting cell for processing and
presentation to reactive T lymphocytes (Budinger and
Hertl, 2000). We find that production of nickel-specific
IL-9 is blocked by anti-class II MHC mAbs but not anti-
class I MHC antibodies supporting the notion that Th9
lymphocytes, but not CD8þ /PU.1þ lymphocytes, are the
predominant source of IL-9 (Figure 3). We also find that
chloroquine, an agent that interferes with the acidification of
the endosome and hence antigen processing (Lombard-Platlet
et al., 1993), interferes with nickel-specific IL-9 production,
which supports the processing-dependent pathway of nickel
presentation.
In some model systems, neutralization of IL-9 enhances
IFN-g production in PBMCs from patients with latent tubercu-
losis infections, suggesting that this cytokine blocks Th1
cytokine secretion (Wu et al., 2008). IL-9 can also enhance
IFN-g production and suppress Th2 responses during active
tuberculosis infections (Finiasz et al., 2007). In our in vitro
assays, exogenous IL-9 did not inhibit nickel-specific IFN-g
production (Figure 4); however, blockade of endogenous IL-9
by using a specific anti-serum enhanced IFN-g production.
Our data indicate that IL-9 acts to regulate allergen-specific
Th1-lymphocyte responses directly (Figure 4d) and indirectly
by enhancing IL-4 production (Figure 4b) by Th2 lymphocytes.
IL-9 gene expression has been implicated in ACD to the hair
dye paraphenylenediamine. PBMCs from allergic, but not
tolerant individuals, increased IL-9 gene expression upon
Table 1. Allergen and patient data
Patient no.1
Age (years)/
gender/race2
Allergen/scoring/
duration (h)3 Studies4
ACD1 59/M/W Epoxy resin/þ /48 ICC
ACD2 68/M/W Thimerosal/þ þ /96 ICC
ACD3 60/M/A Diazolidinyl urea/þ þ /48 ICC
ACD4 46/F/AA Tixocortolpivalate/þ þ þ /96 ICC
ACD5 72/F/W Nickel sulfate/þ /72 ICC
ACD6 54/F/W Nickel sulfate /þ þ þ /72 PCR
ACD7 38/F/W Nickel sulfate /þ þ þ /72 PCR
ACD8 29/F/W Nickel sulfate /þ þ þ /72 PCR
ACD9 41/F//W Nickel sulfate /þ /72 PCR
ACD10 54/F/W Nickel sulfate /þ þ þ /72 PCR
ACD11 43/M/W Cobalt chloride /þ /72 PCR
ACD12 64/F/W Nickel sulfate /þ þ /72 PCR
ACD13 39/F/A Nickel sulfate/þ /48 ELISA
ACD14 62/F/AA Nickel sulfate/þ þ /48, ELISA
Cobalt chloride/þ þ /48
ACD15 58/F/W Nickel sulfate/þ þ þ /72, ELISA
Neomycin/þ /72,
Thimerosal/þ /72
ACD16 29/F/W Nickel sulfate/þ þ /48 ELISA
ACD17 58/F/W Nickel sulfate/þ þ /72, ELISA
Cobalt chloride/þ þ /72
ACD18 25/F/W Nickel sulfate/þ þ /72, ELISA
Cobalt chloride/þ þ /72
ACD19 58/F/AA Nickel sulfate/þ /72, ELISA
Cobalt chloride/þ þ /72
1Patient no. refers to allergic contact dermatitis patients no. ACD1–19.
2Race: A, Asian; AA, African American; W, white (Caucasian).
3Patch–test scoring system: 0, negative;þ , erythema; some induration
(low-level reaction); þ þ , erythema spreading and more marked indura-
tion (moderate reaction); þ þ þ , erythema, marked induration, and
blisters (extreme reaction).
4Studies refers to PCR (real-time PCR), ICC (immunocytochemistry), ELISA
(studies on culture supernatants from allergen-stimulated lymphocytes).
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exposure to this chemical in vitro, suggesting that this cytokine
has a role in ACD (Coulter et al., 2010).
Further experiments in this study demonstrate a regulatory
role of IL-9 in a mouse model of CHS to the strong
Th1-polarizing hapten DNFB. In mouse models of
ACD, using strong lipophilic haptens, Th1 lymphocytes
positively regulate ACD, and have a role in promoting an
inflammatory response via IFN-g production and other
pro-inflammatory cytokines (Saulnier et al., 1995; Xu et al.,
1996). In cytokine gene–targeted mice, IFN-g as well as IL-4
are necessary for sensitization and elicitation, suggesting that
both Th1 and Th2 lymphocytes have a role in murine
ACD (Saulnier et al., 1995; Xu et al., 1996; Campos et al.,
2003). Previous studies of protein contact dermatitis in a
mouse model demonstrated that Th9 lymphocytes are
detectable in the afferent phase of sensitization to topical
polypeptides in BALB/c mice, a phenomenon associated with
Th2-dominant immune response (Lin et al., 2012). Whereas
past work has focused on the effector functions of IL-9 in
allergic inflammation and the role of IL-9 in contact dermatitis
to polypeptides, our study of CHS in IL-9 / mice add-
resses its role in the sensitization/elicitation phases of this
allergic reaction.
Our data indicate that CHS to the Th1-polarizing hapten
DNFB can occur in the absence of IL-9, but its inflammatory
characteristics are altered. We find that there is an enhanced
Th1 response locally, as well as enhanced hapten-specific
IgG2a found in the sera of IL-9 / mice (Figure 5d and e). It
has been established that IgG2a (enhanced in IL-9 / mice) is
dependent on Th1-derived cytokines (Jurado et al., 1989),
whereas IgG1 (not enhanced in IL-9 / mice) is dependent
on Th2-derived cytokines such as IL-4 (Coffman et al., 1989).
Our histologic analysis of skin challenge sites of DNFB-
sensitized mice did not reveal quantitatively significant
differences in the quality of the inflammatory infiltrate in
wild-type or IL-9 / mice (Figure 5b). We noted T lympho-
cytes, neutrophils, and mast cells in both groups of experi-
mental animals. For the hapten DNFB, it is likely that the loss
of the pro-inflammatory effects of IL-9 may have been
mitigated by enhanced Th1 lymphocyte–derived help in the
form of IFN-g, and possibly other cytokines, hence a relatively
preserved ear swelling response in the IL-9 / mice
(Figure 5a). In contrast, under induction of irritant contact
dermatitis by 12-O-tetradecanoylphorbol-13-acetate, ear
swelling inflammatory responses were significantly decreased
in IL-9 / mice compared with WT mice. We hypothesize
that this occurs because (in the absence of inflammatory
effects of IL-9 in knockout mice) the T-cell compensatory
mechanisms observed in ACD (Figure 5a) are not present in
irritant contact dermatitis (Figure 5f).
In total, these in vivo data are consistent with our in vitro
data in humans, showing that Th9 lymphocytes modulate
allergen-specific IFN-g production by Th1 lymphocytes. Our
study contributes to the emerging evidence that Th9 has an
important role in allergic skin reactions, and provides evi-
dence that Th9 and its associated cytokine, IL-9, represent a
potential target for immunotherapy in the treatment of non-
atopic allergic skin diseases.
MATERIALS AND METHODS
Patients
Patients being evaluated for ACD were recruited from University of
Rome and the University of Maryland, Baltimore (Table 1). Written
informed consent was obtained from each patient. The study was
approved by the local institutional review committee and followed
the Declaration of Helsinki Principles for research involving human
subjects. The standard North American Series (Dormer Laboratories,
Toronto, ON, Canada) were applied in 8 mm Finn Chambers (Epitest
Oy, Tuusula, Finland) to upper back of each patient using standard
methods. Results were interpreted with the standard grading system
(0 to 3þ ) at 48 and 72 hours indicated in Table 1. Paired biopsy
samples of positive patch–test sites and normal control skin were
collected and snap-frozen then stored at QUOTE 80oC before RNA
extraction. Patch test–positive biopsies were obtained from additional
patients and frozen in OCT compound for immunohistochemistry
studies. Tonsil sections are used as negative and positive controls for
immunohistochemistry.
Real-time PCR
RNA extraction, complementary DNA synthesis, and quantitative
PCR were performed as previously described (Zhao et al., 2009).
Primer reference sequence accession number and positions
(SABiosciences, Valencia, CA) are as follows: IL-9: NM_000590.1
(Reference position: 353); CD3e: NM_007648.4 (Reference position:
480); PU.1: NM_003120.2 (Reference position: 805); ETS-1:
NM_005238.2 (Reference position 1561); IFN regulatory factor 4:
NM_002460.3 (Reference position 1303); GcN5 (KAT2A):
NM_021078.2 (Reference position 1664); eotaxin gene (CCL11):
NM_002986.2 (Reference position: 285); IL-4: NM_000589.2
(Reference position:122); IFN-g: NM_000619.2 (617); IL-17A:
NM_010552.3 (Reference position:111). For mouse cytokine genes:
IL-4: NM_021283 (Reference position: 46); IFN-g: NM_008337
(Reference position: 309). Levels of 18S mRNA are used to norma-
lize cytokine gene expression levels before calculating fold changes
among patch test–positive and normal skin. For mouse tissue, the
CHS skin was normalized to normal mouse ear skin.
Immunohistochemistry
ACD skin biopsies were embedded in OCT, immediately frozen in
liquid nitrogen, followed by sectioning and fixation in acetone. Slides
were incubated with rabbit anti-human PU.1 polyclonal antibody (Cell
Signaling Technology, Danvers, MA), followed by AlexaFluor594 goat
anti-rabbit IgG (Invitrogen, Carlsbad, CA). For double labeling of T cells
and T-cell subsets, the slides were then incubated with fluorescein
isothicyanate–labeled monoclonal mouse anti-human CD3, CD4, or
CD8 antibodies (BD Pharmingen, San Diego, CA). The slides were
examined by a fluorescence microscope and two color digital images
were recorded. On average, 12 fields from each double-stained section
were counted with a mean of 40 infiltrating cells per field.
In vitro cytokine secretion and hapten-specific antibody ELISA
PBMCs were isolated from allergic patients and nonallergic control
subjects using Accuprep (Accurate Chemical & Scientific, Westbury,
NY). PBMCs were cultured at a concentration of 2 105 ml 1 in
AIM-V medium with 10% fetal bovine serum in triplicate. Cells were
cultured with the pan T-cell mitogen phytohemagglutinin 20mg ml 1,
nickel (1.25, 2.50, 5.00, or 10.00 ml 1), cobalt (1.25, 2.50, 5.00, or
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10.00mg ml 1), or culture medium alone, and were then incubated at
37 1C for 96 hours. Next, supernatants were collected and in vitro
cytokine secretion for IFN-g, IL-2, and IL-4 was measured by Luminex
assay with MILLIPLEX MAP Kit (Millipore, Billerica, MA) and were
assessed for IL-9 production with LEGEND MAX human IL-9 ELISA kit
(Biolegend, San Diego, CA) (limit of detection for IL-9 is 1 pg ml 1)
according to the manufacturer’s instructions (Pickering et al., 2002).
ELISA to detect hapten-specific antibody responses was performed as
previously described (Thatcher et al., 2006).
Blocking IL-9 production in vitro
PBMC were pretreated with either anti-HLA DR (Mouse IgG2a, k,
mAb, L243, Biolegend) or HLA-A,B,C (Mouse IgG2a, k, mAb, W6/32,
Biolegend) at a concentration of 0.25mg ml 1 or 1mg ml 1. In
parallel, they were pre-incubated with chloroquine (Sigma, St. Louis,
MO) at a concentration of 5mM or 20mM for 2 hours, washed
extensively, then incubated with medium containing nickel chloride
or medium alone at 37 1C for 96 hours. Supernatants were collected
for in vitro cytokine IL-9 detection.
Regulation of IFN-c production in vitro by IL-9 or IL-4
PBMCs were incubated with recombinant human IL-9 (R&D Systems,
Minneapolis, MN); human IL-4 (Escherichia coli derived, R&D
Systems) at a concentration of 10, 20, or 100 ng ml 1; or combina-
tions of IL-4 and IL-9 during the stimulation with metal nickel
chloride (10mg ml 1) or medium, and then incubated at 37 1C for
96 hours. Supernatants were collected for in vitro cytokine analysis of
IFN-g, IL-4, and IL-9.
Blocking IL-4 or IL-9 in vitro
PBMCs were incubated with anti-human IL-9 (polyclonal goat IgG,
R&D Systems) at a concentration of 0.5mg ml 1 or 1.0mg ml 1; anti-
human IL-4 (polyclonal goat IgG, R&D systems) at a concentration of
0.5mg ml 1; or normal goat IgG (polyclonal, R&D Systems) at a
concentration of 0.5mg ml 1 during the stimulation with metal nickel
chloride (10mg ml 1) or medium and then incubated at 371C for
96 hours. Supernatants were collected for in vitro cytokine analysis of
IFN-g.
Contact hypersensitivity assay
DNFB CHS experiments with WT and IL-9 / mice were conducted
as previously described (Thatcher et al., 2006). At challenge, both
sides of the ears were treated with DNFB. Ear swelling was calculated
by subtracting the baseline ear thickness from ear thickness 24 hours
after DNFB challenge (Minang et al., 2006). The CHS assay was
repeated twice, and found to be reproducible. For irritant contact
dermatitis, 1% croton oil in acetone was applied to mouse ears as
previously described (Schwarz et al., 1993), and ear swelling was
measured at 24 hours. Skin biopsy specimens were taken from the
pinna of the ear in selected animals at 24 hours after hapten
challenge. These biopsies were paraffin embedded, sectioned onto
glass slides, stained with hematoxylin–eosin, and examined and
photographed using a E600 Nikon microscope equipped with a Spot
Digital camera (Diagnostic Instruments, Sterling Heights, MI).
Experimental mice
The experimental mice were either WT BALB/c mice (H-2d) (Jackson
Labs, Bar Harbor, ME) or IL-9 knockout mice (IL-9 / ) generated on
the BALB/c (H-2d) background in the laboratory of Dr Flavell. The
experimental animals were kept in standard housing conditions, were
fed mouse chow ad libatum, and were exposed to a 12 hour light/dark
cycle. All experimental procedures were reviewed and approved by
the Yale University Institutional Animal Care and Use Committee.
Statistical analysis
The data were expressed as mean±SD of indicated numbers of
experiments with GraphPad Prism 3.03 (GraphPad Software, La Jolla,
CA). The Pearson’s r correlation analysis test was performed with
GraphPad InStat 3.06 (GraphPad Software). The unpaired t-test is
performed for cytokine release; P-values o0.05 were considered
significant. Analysis of variance was used to compare the WT with
IL-9 / mice for dinitrophenyl-specific Ig production.
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